US · DVAX
Dynavax Technologies Corporation
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- EmeryVille, CA 94608
- Website
- dynavax.com
Price · as of 2024-12-31
—
Market cap 1.21B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $40.07 | — |
| Intrinsic Value(DCF) | $9.26 | — |
| Graham-Dodd Method(GD) | $5.62 | — |
| Graham Formula(GF) | $5.60 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $27.80 | $15.66 | $3.51 | $0.00 | $213.38 |
| 2011 | $42.20 | $34.08 | $3.28 | $0.00 | $4.83 |
| 2012 | $19.50 | $26.91 | $2.30 | $0.00 | $182.51 |
| 2013 | $18.90 | $19.80 | $5.43 | $0.00 | $0.00 |
| 2014 | $22.43 | $23.43 | $0.23 | $0.00 | $0.00 |
| 2015 | $16.92 | $26.38 | $2.19 | $0.00 | $169.94 |
| 2016 | $5.90 | $35.92 | $0.00 | $0.00 | $0.00 |
| 2017 | $17.55 | $35.33 | $1.73 | $0.00 | $153.10 |
| 2018 | $8.34 | $328.12 | $0.06 | $0.00 | $0.00 |
| 2019 | $4.22 | $44.40 | $39.37 | $0.00 | $0.00 |
| 2020 | $9.58 | $29.07 | $0.00 | $0.00 | $0.00 |
| 2021 | $9.75 | $232.18 | $743,198.87 | $5.19 | $538.04 |
| 2022 | $9.73 | $119.03 | $57,210.90 | $16.18 | $161.73 |
| 2023 | $13.14 | $34.99 | $14.46 | $4.57 | $2.81 |
| 2024 | $14.40 | $40.07 | $3.89 | $5.62 | $5.60 |
AI valuation
Our deep-learning model estimates Dynavax Technologies Corporation's (DVAX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $40.07
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.26
— upside
Graham-Dodd
$5.62
— upside
Graham Formula
$5.60
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DVAX | Dynavax Technologies Corp… | $10.30 | 1.21B | +289% | -10% | -45% | -46% | 68.57 | 3.14 | 6.75 | 30.92 | — | 3.15 | 82.17% | -1.49% | 9.85% | 4.48% | -2.66% | 2.75% | 0.43 | -0.61 | 10.80 | 9.67 | 3.47 | -50323.00% | 1936.00% | -3763.00% | 3.21% | 0.85 | 43.90% | 0.00% | 0.00% | 5.34% | -342.86 | 23.49 | 5.10 | 2.81 |
| AMPH | Amphastar Pharmaceuticals… | $25.31 | 1.18B | +113% | -65% | -40% | -45% | — | 1.25 | 1.36 | 5.01 | — | 4.41 | 49.46% | 19.50% | 13.63% | 0.00% | 13.00% | 0.00% | 0.06 | 5.51 | 4.02 | 2.70 | -0.82 | -3366.00% | -165.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 63.32% | 5.32 | — | 1.04 | 2.35 |
| BBNX | Beta Bionics, Inc. | $26.51 | 1.17B | +66% | +3,603% | — | — | -6.93 | 1.76 | 5.06 | -4.11 | — | 1.76 | 55.40% | -71.50% | -73.02% | -40.26% | -236.00% | -30.60% | 0.04 | — | 8.66 | 7.64 | 0.26 | -7895.00% | 5394.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -4.20 | — | 3.00 | 6.28 |
| COLL | Collegium Pharmaceutical,… | $35.85 | 1.13B | +124% | +541% | -59% | +70% | 20.98 | 4.37 | 1.69 | 4.41 | — | -2.57 | 59.35% | 23.01% | 8.05% | 23.70% | 14.73% | 3.79% | 2.70 | 2.18 | 1.57 | 1.36 | 1.47 | -699.00% | 2362.00% | 6111.00% | 24.84% | 0.75 | 39.58% | 0.00% | 0.00% | 17.45% | 9.73 | 5.33 | 2.24 | 1.51 |
| ELVN | Enliven Therapeutics, Inc… | $18.50 | 1.1B | — | — | — | — | -11.10 | 3.19 | — | -6.48 | — | 3.19 | 0.00% | — | — | -32.04% | 1991.13% | -29.79% | 0.00 | — | 19.99 | 19.69 | 1.19 | -597.00% | — | 1924.00% | -7.41% | -4.60 | 1394.71% | 0.00% | 0.00% | 2.46% | -6.46 | -9.22 | — | 36.28 |
| EVO | Evotec SE | $3.35 | 1.19B | +735% | -43% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| HROW | Harrow Health, Inc. | $35.42 | 1.31B | +820% | +582% | — | — | -49.72 | 12.48 | 4.35 | 47.49 | — | -7.40 | 75.33% | 4.42% | -8.76% | -24.97% | 4.11% | -4.99% | 3.29 | 0.39 | 2.08 | 1.79 | 8.21 | -3467.00% | 5332.00% | -5906.00% | -7.00% | -0.24 | -28.36% | 0.00% | 0.00% | 0.00% | 119.11 | -17.26 | 5.26 | 1.98 |
| IMTX | Immatics N.V. | $8.94 | 1.09B | +1,746% | -43% | -22% | +246% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| PCRX | Pacira BioSciences, Inc. | $21.85 | 981.78M | +138% | -61% | -17% | -68% | 134.83 | 1.37 | 1.31 | 6.38 | — | 3.11 | 71.50% | 2.64% | 3.68% | 0.96% | 2.60% | 0.50% | 0.01 | 1.10 | 4.54 | 2.34 | -1.19 | -10744.00% | 363.00% | -2355.00% | 14.41% | 1.26 | 18.51% | 0.00% | 0.00% | 53.86% | 41.67 | 5.85 | 1.10 | 1.80 |
| PLSE | Pulse Biosciences, Inc. | $16.27 | 1.09B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
| STAA | STAAR Surgical Company | $25.25 | 1.25B | +51% | -68% | -76% | — | -44.58 | 2.27 | 2.87 | -123.99 | — | 2.28 | 76.32% | -4.02% | -6.44% | -5.16% | -6.20% | -4.05% | 0.10 | — | 5.23 | 4.41 | 18.43 | -19535.00% | -264.00% | 11338.00% | -0.85% | 0.22 | -3.77% | 0.00% | 0.00% | 0.17% | -56.24 | -92.48 | 2.26 | 5.87 |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
- CEO
- Ryan Spencer
- Employees
- 405
- Beta
- 0.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.26 ÷ —) − 1 = — (DCF, example).